Navigation Links
Actavis Receives Approval of Pantoprazole Sodium Delayed-Release Tablets, USP in the U.S.
Date:2/8/2011

MORRISTOWN, N.J., Feb. 8, 2011 /PRNewswire/ -- Actavis Group, an international generic pharmaceuticals company, today announced that it has received approval from the US Food & Drug Administration to market Pantoprazole Sodium Delayed-Release Tablets, USP.  Distribution of the product will commence shortly.  

Pantoprazole Sodium Delayed-Release Tablets 20mg and 40mg, the generic equivalent of Protonix® 20mg and 40mg by Pfizer, had US sales of approximately $1.6 billion for the 12 months ending December 31, 2010, according to IMS Health.    

About Actavis Inc.

Actavis Inc. is the U.S. subsidiary of Actavis Group hf. Approximately one third of Actavis' sales are generated in North America, Actavis' single largest market. Based in Morristown, NJ, Actavis has U.S. manufacturing facilities in Elizabeth, NJ and Lincolnton, NC. Actavis also has research and development facilities in Owings Mills, MD and Sunrise, FL.

About Actavis Group

Actavis is one of the world's leading generic pharmaceutical companies specializing in the development, manufacture and sale of generic pharmaceuticals.  The company has operations in 40 countries, with more than 10,500 employees.

Protonix® is a trademark owned by a party other than Actavis.

Information in this press release may contain forward-looking statements with respect to the financial condition, results of operations and businesses of Actavis.  By their nature, forward-looking statements and forecasts involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially from that expressed or implied by these forward-looking statements. These factors include, among other things, exchange rate fluctuations, the risk that research and development will not yield new products that achieve commercial success, the impact of competition, price controls and price reductions, the risk of loss or expiration of patents or trade marks, difficulties of obtaining and maintaining governmental approvals for products, the risk of substantial product liability claims, exposure to environmental liability.


'/>"/>
SOURCE Actavis Group
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Actavis Receives Approval of Alprazolam ODT in the U.S.
2. Actavis Launches Generic Version of Flomax(R) In The U.S.
3. Sagent Pharmaceuticals and Actavis Enter Into Exclusive U.S. Development, Supply and Marketing Collaboration for a Portfolio of Specialty Injectable Pharmaceutical Products
4. Actavis Receives Approval of Bupropion HCl SR 100mg and 200mg in the U.S.
5. Actavis Receives FDA Approval of Atomoxetine HCl Capsules
6. Actavis Receives Approval of Losartan Potassium Tablets, USP in the U.S.
7. Actavis Receives Approval of Zolpidem Tartrate Extended-Release Tablets, USP 6.25mg CIV in the U.S. with 180-Day Marketing Exclusivity
8. Actavis Inc. Issues a Voluntary Recall of 18 Lots of Fentanyl Transdermal System 25 mcg/h
9. Actavis Encourages Consumers to Return Fentanyl Transdermal System 25 mcg/h
10. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
11. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/6/2017)... Sept. 6, 2017 NeuroRx, a clinical stage biopharma ... and Behavior (ASIB), has been granted Fast Track status by ... of NRX-100 (ketamine HCl) followed by NRX-101 (D-cycloserine + lurasidone). ... trial of this sequential therapy targeting patients who are admitted ... ...
(Date:9/5/2017)...  Just 18 months after its February 2016 launch, ... the appointment of three new senior people to its ... Jones-Phillips and James Wright bring decades ... Tammy Wynne joins as Director, ... She has over ten years, experience in global market ...
(Date:8/31/2017)... PM360,s annual Innovations Issue, published in ... innovations happening across the industry. Established six years ago, ... providing a comprehensive look at the newest and most ... innovative companies, startups, divisions, products, services, and strategies from ... "Everyone in this industry wants to do better—in all ...
Breaking Medicine Technology:
(Date:9/20/2017)... , ... September 20, 2017 , ... Doctors on Liens ... their qualified network of medical professionals working on a personal injury lien basis. Founded ... Surgery Inc brings these esteemed doctors’ vast experience with orthopedic injuries to patients in ...
(Date:9/20/2017)... ... September 20, 2017 , ... Demand generation pioneer True ... edition of MarTech: The Marketing Tech Conference October 2–4, at the Hynes Convention ... speakers — representing such thought-leading companies as JP Morgan Chase, GE Digital, ...
(Date:9/20/2017)... ... September 20, 2017 , ... Compliancy Group is proud ... The Guard®, has helped another long-time client pass their Department of Health and ... the law. , Thanks to the help of the Compliancy Group's Audit Response ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... social campaign, “Humans With Vaginas.” The goal is to ignite conversation via social ... personal care products. The brand has declared September “Humans with Vaginas” month, releasing ...
(Date:9/20/2017)... ... September 20, 2017 , ... Medicare doesn’t ... risk of price gouging for their prescription drugs, according to a new comparison ... isn’t negotiating on our behalf, there’s no consistency in drug pricing among drug ...
Breaking Medicine News(10 mins):